$600M Divestiture: Clarivate Sells Life Sciences & Healthcare to Reduce Debt
CLVT sits 60% above its 52-week low of $1.66.
Summary
Clarivate announced the sale of its Life Sciences & Healthcare business for $600 million to Altaris. This significant divestiture, representing over a third of the company's market cap, will see cash proceeds primarily used to reduce debt by retiring 2028/2029 notes. The move aligns with the company's stated strategy of debt reduction and sharpens its focus on core Academia & Government and Intellectual Property segments. While a non-cash goodwill impairment of $225-$250 million is expected, it will not impact 2026 financial guidance. The transaction is anticipated to close by year-end, pending regulatory approvals.
At the time of this announcement, CLVT was trading at $2.65 on NYSE in the Technology sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $1.66 to $4.77. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.